Clinical anti-cancer drugs entering the market? Kangfang Biotech responds after self-inspection: it is material forged by pharmaceutical representatives.

Recently, news about the entry of Kangfang Biotechnology's clinical trial anti-cancer drug Cardiovascular Nilotinib into the market has drawn industry attention. According to the Elephant News, Li bought 70 doses of the drug for 79,320 yuan, most of which are drugs "for clinical research use only." In response to this, Kangfang Biotechnology told 21st Century Business Herald: "The medical representative forged materials, we will conduct a comprehensive investigation and optimize our business processes, cooperate with regulatory authorities in their investigation, and protect the legitimate rights and interests of patients and the company." A person close to Kangfang Biotechnology also admitted to the reporter: "Although the interpretation of the data is complex, in this treatment area, this result is already considered the best in the world." Many in the industry are not surprised by this result. Some industry insiders have stated that there is still a high unmet clinical need for this treatment area in Western countries such as the United States, and approved treatment options are limited.